FGFR4-driven plasticity in breast cancer progression and resistance to therapy

• Published in: British journal of cancer Vol. 131; no. 1; pp. 11 - 22
• Main Authors: Braun, Marcin, Piasecka, Dominika, Sadej, Rafal, Romanska, Hanna M.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27-07-2024; Nature Publishing Group
• Subjects: 631/67/1347; 692/4028/67/1347; Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cancer Research; Disease Progression; Disease resistance; Drug Resistance; Drug Resistance, Neoplasm; Epidemiology; ErbB-2 protein; Female; Fibroblast growth factor receptor 4; Humans; Metastases; Molecular Medicine; Oncology; Plasticity; Receptor, Fibroblast Growth Factor, Type 4 - genetics; Receptor, Fibroblast Growth Factor, Type 4 - metabolism; Review Article; Signal Transduction
• ISSN: 0007-0920; 1532-1827; 1532-1827
• DOI: 10.1038/s41416-024-02658-y

Breast cancer (BCa) is a complex and heterogeneous disease, with different intrinsic molecular subtypes that have distinct clinical outcomes and responses to therapy. Although intrinsic subtyping provides guidance for treatment decisions, it is now widely recognised that, in some cases, the switch of the BCa intrinsic subtype (which embodies cellular plasticity), may be responsible for therapy failure and disease progression. Aberrant FGFR4 signalling has been implicated in various cancers, including BCa, where it had been shown to be associated with aggressive subtypes, such as HER2-enriched BCa, and poor prognosis. More importantly, FGFR4 is also emerging as a potential driver of BCa intrinsic subtype switching, and an essential promoter of brain metastases, particularly in the HER2-positive BCa. Although the available data are still limited, the findings may have far-reaching clinical implications. Here, we provide an updated summary of the existing both pre- and clinical studies of the role of FGFR4 in BCa, with a special focus on its contribution to subtype switching during metastatic spread and/or induced by therapy. We also discuss a potential clinical benefit of targeting FGFR4 in the development of new treatment strategies.